meta
|
evidence
oncology
Living systematic review and meta-analysis
limited stage SCLC (ls-SCLC)
limited stage SCLC (ls-SCLC) - maintenance (M)
1
limited stage SCLC (ls-SCLC) - 2nd Line (L2)
melanoma (ML)
immune chekpoint inhibitors
anti-CTLA-4
ipilimumab based treatment
ipilimumab alone
Ipilimumab (10 mg/kg)
ipilimumab plus gp100
ipilimumab plus SoC
tremelimumab
anti-PD-(L)1
atezolizumab based treatment
atezolizumab plus cometinib
atezolizumab plus SoC
nivolumab based treatment
nivolumab alone
nivolumab followed by ipilimumab
pembrolizumab based treatment
pembrolizumab alone
pembrolizumab (10mg/kg)
pembrolizumab (10mg/kg) 2 weeks
pembrolizumab (2mg/kg)
pembrolizumab plus SoC
Immune checkpoint association
nivolumab plus ipilimumab
relatlimab plus nivolumab
versus all
vs chemotherapy
vs non platinum-based chemotherapy
vs alkylating agents
vs dacarbazine
vs fotemustine
vs Standard of Care (SoC)
vs placebo plus SoC
vs immune chekpoint inhibitors
vs anti-CTLA-4
vs ipilimumab based treatment
vs ipilimumab alone
vs Ipilimumab (10 mg/kg)
vs ipilimumab plus dacarbazine
vs ipilimumab followed by nivolumab
vs anti-PD-(L)1
vs nivolumab based treatment
vs nivolumab alone
vs pembrolizumab based treatment
vs pembrolizumab alone
vs Immune checkpoint association
vs nivolumab plus ipilimumab
vs Immunostimulant
vs interferon alpha
vs vaccine
vs gp100
vs non active control
vs placebo
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
graph
Evidence gap map
comparisons
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
pembrolizumab alone
pembrolizumab (2mg/kg)
Comparator:
vs Standard of Care (SoC);
Risk of bias:
low;
some concerns;
high;
NA;